Dr Fiona Kerr F.Kerr@napier.ac.uk
Lecturer
Uncovering novel effectors of Nrf2 dysregulation in the progression of Alzheimer's Disease
People Involved
Project Description
Nrf2 activators show pre-clinical promise in the treatment of several neurodegenerative diseases, including Alzheimer’s disease (AD), but exert clinical toxicity. Nrf2 regulates hundreds of anti-oxidant response element (ARE)-containing genes, but their specific roles in mediating the onset and progression of neurodegeneration remains unknown. Using human neuron models, this project aims to uncover the molecular mediators which are essential to Nrf2 neuroprotection in AD, with the aim of identifying new drug targets to harness its protective effects whilst limiting off-target toxicity.
| Status | Project Complete |
|---|---|
| Funder(s) | Alzheimer's Research UK |
| Value | £4,219.00 |
| Project Dates | May 12, 2020 - Dec 31, 2021 |
You might also like
Biochemical Society Summer Vacation Scholarship May 15, 2017 - Jul 10, 2017
Nrf2, a transcriptional activator of cell protection genes, is an emerging target for neurodegenerative conditions including Alzheimer’s disease (AD). Nrf2 activity is reduced in dementia patients and Nrf2 inducing compounds prevent neuronal damage i...
Read More about Biochemical Society Summer Vacation Scholarship.
Do iron-oxide nanoparticles contribute to Parkinsons Disease pathology? Oct 1, 2021 - Nov 21, 2022
Anthropogenic iron-oxide nanoparticles (IONPs) detected in ultrafine particulate matter caused by traffic and industrial emissions have increased substantially over time, constituting one of the most serious threats to human health. However, IONPs ha...
Read More about Do iron-oxide nanoparticles contribute to Parkinsons Disease pathology?.